Live Chat ×
Skip to main content

Advances in Mechanistic TMDD and Platform PBPK Models

Thank you

This live web event has ended. Thank you for attending.

Contributors

  • Dr. Dhaval K. Shah, University at Buffalo, SUNY

    Dr. Shah received a doctorate in pharmaceutical sciences from the University at Buffalo, The State University of New York, and joined UB as an Assistant Professor in 2013. Previously, he held a position of Principal Scientist at Pfizer. Dr. Shah’s research focuses on understanding the determinants for the ADME of protein therapeutics. He is involved in the development of a platform PBPK model for biologics that can characterize and predict the pharmacokinetics of diverse protein therapeutics in several preclinical species and human. Dr. Shah also directs the discovery, development and clinical translation of novel protein therapeutics like antibody-drug conjugates and bi-specific molecules in his laboratory.

  • Dr. Ryan J. Hansen, Eli Lilly and Company

    Dr. Hansen received a doctorate in pharmaceutical sciences from the University at Buffalo, The State University of New York, and joined Lilly as a Senior Pharmacokinetic/Pharmacodynamic (PK/PD) Scientist in 2002 and is currently a Research Adviser at Lilly. Since joining Lilly, Dr. Hansen has implemented the use of quantitative PK/PD analysis as a tool to facilitate the discovery and early development of proteins, and is particularly interested in the field of antibody pharmacokinetics and pharmacodynamics. His innovative modeling and simulation analyses have contributed significantly to the selection and development of many compounds and to the evaluation of technologies and strategies to optimize drug delivery.

April 6, 2017
Thu 12:30 PM EDT

Duration 1H 30M

This live web event has ended.